Regentis Biomaterials names new CEO as Hazum resigns

Regentis Biomaterials Ltd. reported a leadership change following the resignation of Chief Executive Officer Dr. Eli Hazum, effective December 31, 2025.

Accepted by SEC EDGAR 01/06/2026 - 08:08 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regentis Biomaterials Ltd. reported a leadership change following the resignation of Chief Executive Officer Dr. Eli Hazum, effective December 31, 2025. The company states that Dr. Hazum resigned for personal reasons and that his decision was not due to any disagreement with the company.

On the same day, the board appointed its Chairman, Dr. Ehud Geller, as the new Chief Executive Officer. This means the roles of Chairman and CEO are now held by the same person, which may influence how the company’s strategy and governance are managed going forward.

Insights

Corporate governance and leadership analyst

Regentis combines its Chair and CEO roles after a CEO resignation.

Regentis Biomaterials Ltd. disclosed that CEO Dr. Eli Hazum resigned effective December 31, 2025, citing personal reasons and explicitly indicating no disagreement with the company. This framing seeks to distance the change from operational or strategic disputes.

Simultaneously, the board appointed its Chairman, Dr. Ehud Geller, as Chief Executive Officer. Combining the Chair and CEO roles centralizes authority in one individual, which can streamline decision-making but typically reduces separation between oversight and management. The filing also identifies Dr. Geller’s title as Chairman and Chief Executive Officer as of January 6, 2026.

The actual business impact will depend on how consistently the company maintains its existing strategic direction under Dr. Geller’s dual role and whether any future disclosures describe changes in leadership structure, priorities, or board processes following this transition.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Regentis Biomaterials Ltd. (RGNT) disclose?

Regentis Biomaterials Ltd. disclosed that its Chief Executive Officer, Dr. Eli Hazum, resigned effective December 31, 2025, and that Dr. Ehud Geller, previously Chairman of the board, was appointed as the new Chief Executive Officer on the same day.

Why did Regentis Biomaterials Ltd. CEO Dr. Eli Hazum resign?

The company reports that Dr. Eli Hazum resigned as Chief Executive Officer for personal reasons and that his resignation was not due to any disagreement with the company.

Who is the new CEO of Regentis Biomaterials Ltd. (RGNT)?

On December 31, 2025, Regentis Biomaterials Ltd. appointed Dr. Ehud Geller, the Chairman of its board of directors, as Chief Executive Officer.

Does the Chairman of Regentis Biomaterials Ltd. now also serve as CEO?

Yes. The company states that Dr. Ehud Geller serves as both Chairman of the board and Chief Executive Officer, as reflected in the signature block dated January 6, 2026.

Did Regentis Biomaterials Ltd. indicate any disagreement behind the CEO change?

No. The company specifically notes that Dr. Hazum’s resignation is for personal reasons and not due to any disagreement with Regentis Biomaterials Ltd.

When did the CEO transition at Regentis Biomaterials Ltd. (RGNT) take effect?

The CEO transition became effective on December 31, 2025, when Dr. Eli Hazum resigned and Dr. Ehud Geller was appointed Chief Executive Officer on the same day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2026

Commission file number: 001-42834

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On December 31, 2025, Dr. Eli Hazum resigned as the Chief Executive Officer of Regentis Biomaterials Ltd. (the “Company”) effective immediately. Dr. Hazum has indicated his resignation is for personal reasons and not due to any disagreement with the Company.

On the same day, the Company appointed Dr. Ehud Geller, the Chairman of the Company’s board of directors, as Chief Executive Officer.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.
Date: January 6, 2026	By:	/s/ Dr. Ehud Geller
	Name:	Dr. Ehud Geller
	Title:	Chairman and Chief Executive Officer

2